Core Viewpoint - As of August 5, 2023, AAPG's stock price increased by 10.37%, reaching $41.5 per share, with a total market capitalization of $3.858 billion. The company reported a total revenue of 981 million RMB for the year ending December 31, 2024, representing a year-on-year growth of 341.77%, while the net profit attributable to shareholders was -405 million RMB, showing a growth of 56.2% year-on-year [1][2]. Company Overview - AAPG is a biopharmaceutical company based in China, focusing on developing innovative drugs for cancer, hepatitis B, and age-related diseases. The company was listed on the Hong Kong Stock Exchange on October 28, 2019, under the stock code 6855.HK [2]. - The company has developed a proprietary platform for protein-protein interaction targeted drug design and is at the forefront of new drug development in the apoptosis pathway. AAPG has established a pipeline of nine Class 1 small molecule new drugs that have entered clinical development [2]. - AAPG's core product, Orebatinib (brand name: Nairike), has been approved in China and is included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2022). It has also received various designations from the FDA and the EU [2]. Clinical Development and Collaborations - The company is conducting over 40 clinical trials across China, the United States, Australia, and Europe. It has received 16 FDA orphan drug designations and 2 FDA fast track designations for its investigational drugs [2]. - AAPG has engaged in collaborations with leading biotechnology and pharmaceutical companies and academic institutions, including UNITY, MD Anderson, Mayo Clinic, Dana-Farber Cancer Institute, Merck, AstraZeneca, and Pfizer [2]. - The company has undertaken several national science and technology major projects, including five under the "Major New Drug Creation" initiative, and is committed to enhancing its R&D capabilities and accelerating the clinical development of its product pipeline [2].
亚盛医药上涨10.37%，报41.5美元/股，总市值38.58亿美元